No increased CV risk with systemic psoriasis therapies?

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2011年 / 1367卷 / 1期
关键词：
Psoriasis; Infliximab; Etanercept; Adalimumab; Plaque Psoriasis;
D O I：
10.2165/00128415-201113670-00006
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3 / 3
相关论文
共 50 条
  • [41] Use of systemic therapies for psoriasis in the COVID-19 era
    Kearns, Donovan G.
    Uppal, Shelley
    Chat, Vipawee S.
    Wu, Jashin J.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (02) : 622 - 625
  • [42] Biological therapies in the systemic management of psoriasis: International Consensus Conference
    Sterry, W
    Barker, J
    Boehncke, WH
    Bos, JD
    Chimenti, S
    Christophers, E
    de la Brassinne, M
    Ferrandiz, C
    Griffiths, C
    Katsambas, A
    Kragballe, K
    Lynde, C
    Menter, A
    Ortonne, JP
    Papp, K
    Prinz, J
    Rzany, B
    Ronnevig, J
    Saurat, JH
    Stahle, M
    Stengel, FM
    van de Kerkhof, P
    Voorhees, J
    BRITISH JOURNAL OF DERMATOLOGY, 2004, 151 : 3 - 17
  • [43] Psoriasis is associated with increased mortality risk
    Kimball, Alexa
    Guerin, Annie
    Mulani, Parvez
    Bao, Yanjun
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 62 (03) : AB67 - AB67
  • [44] Increased risk of psoriasis with terbinafine, itraconazole
    Reactions Weekly, 2017, 1680 (1) : 11 - 11
  • [45] Psoriasis associated with increased tumor risk
    Krome, Susanne
    AKTUELLE DERMATOLOGIE, 2020, 46 (03) : 75 - 75
  • [46] Increased CV risk with glucocorticoids in Cushing's
    Reactions Weekly, 2012, 1413 (1) : 1 - 1
  • [47] Testosterone products: increased risk of CV disorders
    Reactions Weekly, 2016, 1588 (1) : 4 - 4
  • [48] Increased CV-Risk if Breakfast is skipped
    Kessing, Richard
    AKTUELLE KARDIOLOGIE, 2019, 8 (04) : 262 - +
  • [49] Atorvastatin and clopidogrel interaction: increased CV risk?
    Reactions Weekly, 2006, 1114 (1) : 1 - 1
  • [50] Tocilizumab: no increased CV risk versus etanercept
    Reactions Weekly, 2018, 1685 (1) : 11 - 11
12345